Javier Puente

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake et al. · Journal of Clinical Oncology · 2016 · 742 citations · Full text

Pharmacotherapy, Immunotherapeutics, Immunotherapy +16

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

Elena Castro, Nuria Romero-Laorden, Ángela del Pozo et al. · Journal of Clinical Oncology · 2019 · 366 citations · Full text

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg et al. · The Lancet · 2021 · 313 citations · Full text

Urology, Oncology, Genitourinary Cancer +6

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 263 citations · Full text

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

Jesús García-Donás, Emilio Esteban, Luis J. Leandro‐García et al. · The Lancet Oncology · 2011 · 220 citations

Urology, Genitourinary Cancer, Medicine +7